TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05540509

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based intervention
Description: Mothers were given physical activity goals and coping resources to practice at home and were asked to record their experiences on an activity log. Course content was taught from a detailed training manual and was based on concepts and strategies from social cognitive theory that have been effective in increasing physical activity and fitness levels among mothers. In the first month, mothers attended group exercise sessions twice per week (total of eight group sessions) and exercised on their own once per week. In the second month, mothers attended group exercise sessions once per week (total of four group sessions) and exercised on their own twice per week. In the third month, mothers exercised on their own three times per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-based intervention
Description: The HBI group received information on building social support and reducing physical activity barriers based on materials from the Diabetes Prevention Program. Participants were also given activity logs to record their physical activity each week, which was collected by research staff at each monthly assessment time point to assess how participants were progressing with their physical activity goals. Mothers exercised on their own for three months with the goal of meeting national physical activity guidelines
Study: NCT01186588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: One 300-mg dose of canagliflozin on Day 1
Study: NCT01737671

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ommaya Reservoir
Description: Surgical catheter placement into the fourth ventricle of the brain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 2 mg into fourth ventricle of the brain via the Ommaya Reservoir for 4 days. Each patient will undergo three cycles with at least two weeks between each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 5 mg/square meter per dose administered every 6 hours by vein or mouth.
Study: NCT03195985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Description: A shortened, 4 week mindfulness intervention course based on the original 8 week mindfulness-based stress reduction course by Jon Kabat-Zinn

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Age Well psycho-education
Description: 4-week active control condition aimed at psycho-education regarding healthy ageing
Study: NCT04228952

Intervention type: COMBINATION_PRODUCT
Intervention: Modified Natural American Spirit-Tan or Green cigarettes injected with labeled NNK
Description: American Spirit cigarettes will be modified by adding 0.300 μg \[pyridine-D4\]NNK to each cigarette so that the amount of total (deuterated plus unlabeled) NNK in these cigarettes is below 0.700 μg/g tobacco.

Intervention type: COMBINATION_PRODUCT
Intervention: Modified Natural American Spirit-Tan or Green cigarettes injected with labeled NNK
Description: American Spirit cigarettes will be modified by adding 0.300 μg \[pyridine-D4\]NNK to each cigarette so that the amount of total (deuterated plus unlabeled) NNK in these cigarettes is below 0.700 μg/g tobacco.
Study: NCT03465566

Intervention type: DIAGNOSTIC_TEST
Intervention: IDS;MMSPE;CDI 2;CBCL;tests of facial expression evaluation
Description: Five pictures (including nonfacial features; i.e., hairs) were used for each emotion, giving a total of 25 trials.Stimuli consist of pictures of facial affect taken from the Ekman and Friesen series.

Intervention type: DIAGNOSTIC_TEST
Intervention: IDS;MMSPE;CDI 2;CBCL;tests of facial expression evaluation
Description: Five pictures (including nonfacial features; i.e., hairs) were used for each emotion, giving a total of 25 trials.Stimuli consist of pictures of facial affect taken from the Ekman and Friesen series.
Study: NCT03614195

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MCDTT
Description: The MCDTT group will undertake sitting to standing, standing balance, and treadmill walking training while concurrently perform motor and cognitive tasks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MDTT
Description: The MDTT group will train the same set of sitting to standing, standing balance, and walking activities as the MCDTT group while simultaneously performing only motor task.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CDTT
Description: The CDTT group will train the same set of sitting to standing, standing balance, and walking activities as the MCDTT group while simultaneously performing only cognitive task.
Study: NCT00487227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caffeine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caffeine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caffeine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03814343

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amphotericin B in 30% DMSO
Description: amphotericin B in 30% DMSO was given to patients in active comparators group for continuous 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 30% DMSO
Description: 30% DMSO was given to patients in placebo comparators group for continuous 12 weeks.
Study: NCT01550588

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device closure
Description: PFO Amplatzer device closure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard medical treatment
Description: Standard Medical management using anti-coagulant therapy
Study: NCT02026453

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist obtains admission medication history

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacy technician obtains admission medication history
Study: NCT01802502

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral rifampicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral rifampicin
Study: NCT02329756

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid (TXA)
Description: 1g Tranexamic Acid (TXA) will be given at the time of delivery. If in 30 minutes, heavy bleeding continues, a 2nd dose will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9%
Description: Dose 1: 1 gram - to be administered by intravenous injection at an approximate rate of 1 mL/minute to all randomized women approximately 10 minutes prior to induction of anesthesia~Dose 2: 1 gram - If 30 minutes after beginning the cesarean section there is significant bleeding as defined by the need for the transfusion of 4 or more units of blood products, or if there is a rebleed within the 24 hours after the first dose, a second dose may be given. To be administered by intravenous injection at an approximate rate of 1 mL/minute.~The trial treatment injections should not be mixed with blood for transfusion, or infusion solutions containing penicillin or mannitol.
Study: NCT00861965

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloStim-8
Description: intravenous infusion of mis-matched AlloStim-8

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloStim-8
Description: intravenous infusion of AlloStim-8 on day 7

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloStim-8
Description: intravenous infusion of AlloStim-8 on day 14

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloStim-8
Description: intravenous infusion of AlloStim-8 on day 21
Study: NCT02550223

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radial artery Catheterization
Description: Insertion of radial artery catheter for sampling and blood pressure measurement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radial artery Catheterization
Description: Insertion of radial artery catheter for sampling and blood pressure measurement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radial artery Catheterization
Description: Insertion of radial artery catheter for sampling and blood pressure measurement
Study: NCT02907203

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug Coated Balloon
Description: Prospective, multi-center, single-arm study characterizing outcomes in subjects with Peripheral Artery Disease (PAD) lesions treated with percutaneous transluminal angioplasty (PTA) using the GORE® DCB Catheter.
Study: NCT00747188

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PBL
Study: NCT00755326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HLXL
Description: Two daily dosages will be investigated. Huo-Luo-Xiao-Ling (HLXL) dose (10 capsules/day or 4,000mg/day) in the first 2 weeks to evaluate safety. If no adverse effects were observed, the dose was increased to 14 capsules per day (5,600 mg/ day) for the subsequent 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HLXL
Description: Two daily dosages will be investigated. Huo-Luo-Xiao-Ling (HLXL) dose (10 capsules/day or 4,000mg/day) in the first 2 weeks to evaluate safety. If no adverse effects were observed, the dose was increased to 14 capsules per day (5,600 mg/ day) for the subsequent 6 weeks.
Study: NCT01808664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized Patient Instructor Intervention
Description: In each case, patients will harbor underlying concerns about a serious underlying condition (e.g., either disc herniation or osteoporosis) and will request inappropriate tests. Standardized patient instructors (SPIs) will portray new patients visiting the clinic for the first time, and electronic medical records will be identical to that of actual new patients.~During the initial part of intervention visits, SPIs will assess the extent to which PCPs engage in patient-centered techniques specified in the final intervention model. SPIs will then break of their role and either teach or reinforce PCP use of the techniques, presenting techniques in a logical sequence while emphasizing flexibility in their use. SPIs will use scripts to deliver the interventions, providing opportunities for PCPs to ask questions, discuss concepts, and practice (by role playing) patient-centered techniques.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: In the latter half of visits with control PCPs, standardized patient instructors will share information with physicians regarding the acute low back pain self-care and bone health, but will not discuss patient-centered techniques or conduct training. The total duration of the control information sharing will be about one-third the SPI intervention to enhance patient-centeredness.
Study: NCT03732170

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TotalFill® Bioceramic sealer
Description: The participant will be treated with TotalFill® Bioceramic sealer.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AH plus® sealer
Description: The participant will be treated with AH plus® sealer.
Study: NCT04126811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate, Pirarubicin, Ifosfamide
Description: Apatinib 500mg, orally, once a day. One cycle every 4 weeks. Pirarubicin 75mg/m2 D1, intravenous infusion for 1-2 hours; every 4 weeks. Ifosfamide 2g/m2/d D1-D5, intravenously for 4-6 hours, 1 cycle every 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apatinib Mesylate
Description: Apatinib 500mg, orally, once a day. One cycle every 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirarubicin, Ifosfamide
Description: Pirarubicin 75mg/m2 D1, intravenous infusion for 1-2 hours; every 4 weeks. Ifosfamide 2g/m2/d D1-D5, intravenously for 4-6 hours, 1 cycle every 4 weeks
Study: NCT00699504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cangrelor
Description: IV bolus 60 mcg/kg; 8 mcg/kg x 3 hrs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cangrelor
Description: 30 mcg/kg bolus; 4 mcg/kg/min x 3 hrs. Oral placebo capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cangrelor
Description: 60 mcg/kg bolus; 8 mcg/kg/min x 3 hrs. Oral placebo capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: 400 mg orally. Placebo IV bolus and infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo IV and oral
Study: NCT03164603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NLG802
Description: Indoleamine 2,3-Dioxygenase (IDO) Inhibitor
Study: NCT01608581

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multimedia burn awareness campaign
Description: Television commercials x4 delivered 86 times over 10 days plus logo in print media daily in two papers in two cities
Study: NCT02968485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR7390
Description: SHR7390 is provided as white, film-coated,immediate release tablets containing SHR7390 at dosage strengths of 0.125 mg and 0.5 mg. Multiple tablets of SHR7390 will be administered daily to achieve targeted doses of SHR7390: 0.25 mg-4 mg. Tablets will be orally administered with 240 ml water, once daily, 2 hours after a meal.
Study: NCT02831569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loxoprofen sodium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methocarbamol
Study: NCT03791749

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding Support
Description: 12-minute simple technique
Study: NCT02621775

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based stress management program
Description: The program includes 5 one hour weekly sessions that patient follow from a web site accessible from a computer in our unit. He benefits from a minimal contact with a medical member of staff before and after every session. The duration of each session is about one hour. To avoid internet connexion problem between session it is supplied to the patient, from the first session an USB key (Universal Serial Bus) containing videos, audio files, self help book, portfolio in the form of e-guide, log book with the program of the exercises to be realized between two session of the five sessions program. The patient is encouraged to practice a twenty-minutes daily exercises five or six days per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress management in face-to-face
Description: The program includes 5 forty-five minutes weekly session with a therapist (psychologist graduate of a master of cognitive and emotional therapy with a minimal of one year of practice in CBT and CBSM (Cognitive-Behavioral Stress Management ). Information, exercises and homework assignments are delivered by the therapist without self help support.

Intervention type: OTHER
Group type: OTHER
Intervention: Waiting list
Description: The patients are followed by their General Practitioners without change in treatment .
Study: NCT00571428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arformoterol Tartrate Inhalation Solution
Description: Nebulized arformoterol tartrate inhalation solution 15 microgram twice a day (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arformoterol Tartrate Inhalation Solution
Description: Nebulized arformoterol tartrate inhalation solution 15 microgram twice a day (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arformoterol Tartrate Inhalation Solution
Description: Nebulized arformoterol tartrate inhalation solution 30 microgram once a day (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arformoterol Tartrate Inhalation Solution
Description: Nebulized arformoterol tartrate inhalation solution 30 microgram once a day (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo inhalation solution (citrate buffered 0.9% saline solution) once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo inhalation solution (citrate buffered 0.9% saline solution) once a day
Study: NCT01434966

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbopelvic Manipulation
Description: The lumbopelvic joint manipulation (Grade V mobilization) will be performed on the ipsilateral side of the test limb. The participant will be passively side-bent towards and rotated away from the selected lumbopelvic region which is followed by the delivery of a posterior/inferior force through the opposite anterior superior iliac spine. If a cavitation is not heard or felt by the patient or clinician, the technique will be repeated. If the second attempt does not produce cavitation the procedure will be repeated on the contralateral side using similar methods. If cavitation is not heard or felt by the participant or clinician following the second attempt on the contralateral side, the participant will proceed with the assessment of quadriceps strength and activation as usual.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TENS- Spine
Description: The TENS electrodes will be applied lateral to L1 and L2 and lateral to S5 and S1. The TENS unit will be set to deliver a continuous TENS biphasic pulsatile current at 150 Hz, with a phase duration of 150 microseconds. The TENS unit will be worn during all exercise testing and for the first 30 minutes of quadriceps force output and activation testing. After the 30 minute post-intervention measures (Post30) are obtained, the TENS unit will be turned off.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TENS- Knee
Description: The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. Care will be taken not to place TENS electrodes on the quadriceps muscles or muscles of the anterior leg. The TENS unit will be set to deliver a continuous TENS biphasic pulsatile current at 150 Hz, with a phase duration of 150 microseconds. The TENS unit will be worn during all exercise testing and for the first 30 minutes of quadriceps force output and activation testing. After the 30 minute post-intervention measures (Post30) are obtained, the TENS unit will be turned off.
Study: NCT02171052

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran etexilate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin
Study: NCT04087395

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RHA®4 with new anesthetic agent
Description: A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 23 mg/g and 0.3% w/w of new anesthetic agent in a physiologic buffer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RHA®4-Lidocaine
Description: A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 23 mg/g and 0.3% w/w lidocaine in a physiologic buffer.
Study: NCT01309945

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Capsule, Oral, 30-60 mg/day, once daily (QD), 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching with BMS-820836
Description: Tablet, Oral, 0.0 mg, once daily (QD), 14 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-820836
Description: Tablet, Oral, 0.5-2.0 mg, once daily (QD), 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Capsule, Oral, 30-60 mg/day, once daily (QD), 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching with Duloxetine
Description: Tablet, Oral, 0.0 mg, once daily (QD), 8 weeks
Study: NCT00776503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VORINOSTAT
Description: vorinostat; 400mg once daily; increasing duration (7-10-14 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VORINOSTAT
Description: vorinostat; 400mg once daily; increasing duration (7-10-14 days)
Study: NCT03552757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide 1.0 mg
Description: Subcutaneous (s.c.) injections of semaglutide once weekly at an escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week). The dose will be escalated to next level every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg
Description: Subcutaneous injections of semaglutide once weekly at an escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week, 1.7 mg/week and 2.4 mg/week). The dose will be escalated to next level every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo I (Semaglutide)
Description: S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide 2.4 mg (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week, 1.7 mg/week and 2.4 mg/week). The dose will be escalated to next level every 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo I (Semaglutide)
Description: S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide 2.4 mg (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week, 1.7 mg/week and 2.4 mg/week). The dose will be escalated to next level every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo II (Semaglutide)
Description: S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide 1.0 mg (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week). The dose will be escalated to next level every 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo II (Semaglutide)
Description: S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide 1.0 mg (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week). The dose will be escalated to next level every 4 weeks.
Study: NCT03256110

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improving Communication about Serious Illness-AI/AN
Description: A one-page summary of patient-specific preferences, barriers and facilitators for engaging in patient-provider communication about advance care planning, provided to patient and provider prior to a clinical encounter with prompts for initiating and/or improving the quality of communication about advance care planning.